Correlation Between Madrigal Pharmaceuticals and Reviva Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Madrigal Pharmaceuticals and Reviva Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Madrigal Pharmaceuticals and Reviva Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Madrigal Pharmaceuticals and Reviva Pharmaceuticals Holdings, you can compare the effects of market volatilities on Madrigal Pharmaceuticals and Reviva Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Madrigal Pharmaceuticals with a short position of Reviva Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Madrigal Pharmaceuticals and Reviva Pharmaceuticals.

Diversification Opportunities for Madrigal Pharmaceuticals and Reviva Pharmaceuticals

-0.58
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Madrigal and Reviva is -0.58. Overlapping area represents the amount of risk that can be diversified away by holding Madrigal Pharmaceuticals and Reviva Pharmaceuticals Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Reviva Pharmaceuticals and Madrigal Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Madrigal Pharmaceuticals are associated (or correlated) with Reviva Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Reviva Pharmaceuticals has no effect on the direction of Madrigal Pharmaceuticals i.e., Madrigal Pharmaceuticals and Reviva Pharmaceuticals go up and down completely randomly.

Pair Corralation between Madrigal Pharmaceuticals and Reviva Pharmaceuticals

Given the investment horizon of 90 days Madrigal Pharmaceuticals is expected to generate 0.65 times more return on investment than Reviva Pharmaceuticals. However, Madrigal Pharmaceuticals is 1.54 times less risky than Reviva Pharmaceuticals. It trades about 0.11 of its potential returns per unit of risk. Reviva Pharmaceuticals Holdings is currently generating about 0.02 per unit of risk. If you would invest  24,600  in Madrigal Pharmaceuticals on September 5, 2024 and sell it today you would earn a total of  7,536  from holding Madrigal Pharmaceuticals or generate 30.63% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy98.44%
ValuesDaily Returns

Madrigal Pharmaceuticals  vs.  Reviva Pharmaceuticals Holding

 Performance 
       Timeline  
Madrigal Pharmaceuticals 

Risk-Adjusted Performance

8 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Madrigal Pharmaceuticals are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite quite conflicting technical and fundamental indicators, Madrigal Pharmaceuticals disclosed solid returns over the last few months and may actually be approaching a breakup point.
Reviva Pharmaceuticals 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Reviva Pharmaceuticals Holdings are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak basic indicators, Reviva Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Madrigal Pharmaceuticals and Reviva Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Madrigal Pharmaceuticals and Reviva Pharmaceuticals

The main advantage of trading using opposite Madrigal Pharmaceuticals and Reviva Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Madrigal Pharmaceuticals position performs unexpectedly, Reviva Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Reviva Pharmaceuticals will offset losses from the drop in Reviva Pharmaceuticals' long position.
The idea behind Madrigal Pharmaceuticals and Reviva Pharmaceuticals Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Other Complementary Tools

Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Fundamental Analysis
View fundamental data based on most recent published financial statements